BLADDER CANCER: A FIRST IN FRANCE
DECEMBER 15, 2025 In the spotlight, astatine-211, an alpha-emitting radionuclide with high cytotoxic potential that will enable a major step…
Atonco press release
đź“° Other categories:
-
-
CLINICAL ALPHATHERAPY STATUS – NOVEMBER 2025
Atonco Report: Overview of clinical developments in alpha-emitter radiotherapy Atonco publishes its November 2025 report outlining the state of clinical…
-
ATONCO ANNOUNCES THE APPOINTMENT OF DR. ALEXANDRA (GITEAU) PAILLARD AS CHIEF OPERATING OFFICER
Atonco, an innovative company specializing in the development of next-generation radiopharmaceuticals based on astatine-211, today announces the promotion of Alexandra…
-
ATO-101™: A THERAPEUTIC ADVANCE FOR THE TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
Atonco is proud to announce that the results of preclinical and clinical studies have been published in the journal Cancers…
-
ATONCO AND GIP ARRONAX SIGN DEVELOPMENT AGREEMENT FOR AN INNOVATIVE RADIOPHARMACEUTICAL FOR ALPHA RADIOTHERAPY
Atonco and GIP ARRONAX (Saint-Herblain, France) are joining forces to take a new step forward in the implementation of alpha-immunotherapy…
-
ATONCO AND THE UNIVERSITY OF MICHIGAN ANNOUNCE COLLABORATION FOR THE PHASE 1-2a CLINICAL STUDY OF ATO-101™
Atonco, a French biotechnology company, and the University of Michigan today announced a collaboration agreement to conduct a targeted alpha-therapy…
-
TARGETED ALPHA THERAPY CANDIDATE: RECRUITMENT COMPLETED FOR BLADDER CANCER STUDY
Telix (Melbourne, Australia) and Nantes-based company ATONCO S.A.S. (‘ATONCO’) today announced that the last patient has been treated in a…
-
IONETIX AND ATONCO SIGN PARTNERSHIP AGREEMENT TO FIGHT BLADDER CANCER
Atonco (Nantes-Saint Herblain, France) and Ionetix (Lansing, MI, USA) have signed a partnership agreement to ensure GMP manufacturing and supply…
-
FIRST PATIENT RECEIVES DOSE IN TARGETED ALPHA THERAPY FEASIBILITY STUDY FOR BLADDER CANCER
Atonco announces that a first patient has been dosed in the Phase I ‘PERTINENCE’ study of TLX250-CDx in patients with…
-
ATONCO AND ICO NANTES ANGERS: CLINICAL PARTNERS IN THE FIGHT AGAINST CANCER
ATONCO S.A.S. (‘ATONCO’) today announces that it has entered into a clinical research partnership agreement with the Institut de CancĂ©rologie…
-
ATONCO ANNOUNCES THE APPOINTMENT OF ADRIEN REYMOND AS DIRECTOR OF REGULATORY AFFAIRS AND QUALITY ASSURANCE
Atonco today announces that Adrien Reymond, PharmD, B.Eng and EMBA candidate, will lead regulatory affairs and quality. Adrien brings 15…
-
ATONCO ANNOUNCES THE APPOINTMENT OF SYLVAIN FANIER AS NEW CHAIRMAN OF ATONCO
Atonco today announces that Sylvain Fanier, MSc. EMBA, will succeed Professor Jean-François Chatal as Chairman effective March 16, 2020. Sylvain…
-
TELIX PARTNERS WITH FRENCH COMPANY ATONCO TO FIGHT BLADDER CANCER
Australian biopharmaceutical company Telix Pharmaceuticals Limited (ASX: TLX) has signed an agreement with French company ATONCO S.A.S. to study the…